Selpercatinib(LOXO-292) chemical structure
Chemical structureResearch use only
CAT. NO. DC11450Featured

Selpercatinib(LOXO-292)

Pack Sizes & Prices

TotalUS$550
We match the best price and quality on market.
Product overview

Description & Application

Selpercatinib is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively[1]. Antineoplastic activity[2].

ParameterValue
Chemical NameSelpercatinib
CAS No.2152628-33-4
SynonymsLOXO-292， LOXO292，LOXO 292
FormulaC29H31N7O3
M.Wt525.61
SMILESN#CC1=C2C(C3=CC=C(N4CC(C5)N(CC6=CC=C(OC)N=C6)C5C4)N=C3)=CC(OCC(C)(O)C)=CN2N=C1
Purity>98%
Storage2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO

Biological Activity

Selpercatinib is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively[1]. Antineoplastic activity[2].

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

[1]. Steven W. Andrews, et al. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors. WO2018071447A1.

[2]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 32, No. 4, 2018.

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Product documentation

View online datasheetRequest COA / MSDS

Refer to the certificate supplied with your lot for batch-specific release results.

Handling guide

2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO

Solution calculator

Related research products

Enbezotinib chemical structureDC48424

Enbezotinib

Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer[1].

View activity & prices
Rociletinib (CO-1686) chemical structureDC7106

Rociletinib (CO-1686)

Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.

View activity & prices
CH5424802(Alectinib) chemical structureDC7383

CH5424802(Alectinib)

The dissociation constant (KD) value of CH5424802 For ALK in an ATP-competitive manner is 2.4 nM. CH5424802 has substantial inhibitory potency against both native ALK and L1196M with Ki of 0.83 nM and 1.56 nM,…

View activity & prices
Nintedanib (BIBF 1120) chemical structureDC7084

Nintedanib (BIBF 1120)

BIBF 1120 is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

View activity & prices
Motesanib Diphosphate (AMG-706) chemical structureDC7200

Motesanib Diphosphate (AMG-706)

Motesanib Diphosphate is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than…

View activity & prices

Cart

Request quotation